The Clinical Core will provide the clinical trial infrastructure to support the clinical trial and related translational research that is generated by the four projects that constitute this SPORE application. The components of the Clinical Core leverage the extensive resources and expertise at MD Anderson in clinical and translational research. As the research efforts proposed in the current application represent extensions and expansions of ongoing efforts, the Clinical Core will continue to provide the support and expertise to develop and manage the highly innovative clinical trials that develop from the proposed research efforts. Additionally, recognizing that the scope of clinical trials may encompass from early stage (proof-of principle) studies examining drug/agent delivery and tissue-based efficacy (i.e. pharmacodynamics) to larger, randomized multicenter clinical trials, we have developed a robust web-based clinical trials management software package, the Data Management Initiative (DMI). This system supports state-of-the art tracking of all critical elements of the clinical trial including patient outcomes, adverse events and drug dosing. It contains internal auditing functions thereby limiting resource consuming queries. Furthermore, the DMI has been approved by the FDA for studies containing IND agents and is also approved for registration clinical trials. The Clinical Core will support the specific SPORE projects as described: Project 1: A Phase l/ll study combining the Delta-24 oncolytic virus with temozolomide. Early phase study of evaluating mesenchymal stem cell mediated delivery of Delta-24 into human glioblastoma. Project 2: A Phase I study of combination signal transduction agents followed by a 2-stage multi-arm Bayesian based Adaptive Selection Design clinical trial to test preclinical developed drug combinations. Project 3: No direct Clinical Core support needed for these clinical-molecular studies using outcomes and molecular profiles from large clinical trials. Project 4: A Phase I clinical trial of WPI 066 an oral STAT3 inhibitor with an arm that will evaluate treatment delivery and impact on molecular targets (pharmacokinetics and pharmacodynamics).
The Clinical Core will provide the clinical trials infrastructure to enable the innovative clinical studies that are developed within each of the SPORE projects to be completed with the highest level of oversight and data quality. The Clinical Core has developed resources to support early stage studies that examine treatment effects on the tumor to large scale multi-center studies.
|Wang, Yugang; Xia, Yan; Lu, Zhimin (2018) Metabolic features of cancer cells. Cancer Commun (Lond) 38:65|
|Noh, Hyangsoon; Zhao, Qingnan; Yan, Jun et al. (2018) Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185|
|Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7|
|Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427|
|Wang, Qianghu; Hu, Baoli; Hu, Xin et al. (2018) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 33:152|
|Dong, Jianwen; Park, Soon Young; Nguyen, Nghi et al. (2018) The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget 9:10497-10509|
|Thomas, Jonathan G; Parker Kerrigan, Brittany C; Hossain, Anwar et al. (2018) Ionizing radiation augments glioma tropism of mesenchymal stem cells. J Neurosurg 128:287-295|
|Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310|
|Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39|
|Lu, Sean; Wang, Yugang (2018) Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Commun (Lond) 38:63|
Showing the most recent 10 out of 232 publications